Opening book details…
Can I read Heterodimeric IL-15 in Cancer Immunotherapy on EtoBox?
Heterodimeric IL-15 in Cancer Immunotherapy by Bergamaschi, Cristina (author);Stravokefalou, Vasiliki (author);Stellas, Dimitris (author);Karaliota, Sevasti (author);Felber, Barbara K. (author);Pavlakis, George N. (author) is a Medicine article available to read on EtoBox.
What is Heterodimeric IL-15 in Cancer Immunotherapy about?
Immunotherapy has emerged as a valuable strategy for the treatment of many cancer types. Interleukin-15 (IL-15) promotes the growth and function of cytotoxic CD8+ T and natural killer (NK) cells. It also enhances leukocyte trafficking and stimulates tumor-infiltrating lymphocytes expansion and activity. Bioactive IL-15 is produced in the body as a heterodimeric cytokine, comprising the IL-15 and the so-called IL-15 receptor alpha chain that are together termed “heterodimeric IL-15” (hetIL-15). hetIL-15, closely resembling the natural form of the cytokine produced in vivo, and IL-15:IL-15Rα complex variants, such as hetIL-15Fc, N-803 and RLI, are the currently available IL-15 agents. These molecules have showed favorable pharmacokinetics and biological function in vivo in comparison to single-chain recombinant IL-15. Preclinical animal studies have supported their anti-tumor activity, suggesting IL-15 as a general method to convert “cold” tumors into “hot”, by promoting tumor lymphocyte infiltration. In clinical trials, IL-15-based therapies are overall well-tolerated and result in the expansion and activation of NK and memory CD8+ T cells. Combinations with other immunotherapies ar
Who reads Heterodimeric IL-15 in Cancer Immunotherapy?
It is typically read by researchers, students, and practitioners in Medicine.
- Author
- Bergamaschi, Cristina (author);Stravokefalou, Vasiliki (author);Stellas, Dimitris (author);Karaliota, Sevasti (author);Felber, Barbara K. (author);Pavlakis, George N. (author)
- Publisher
- MDPI AG
- Published
- 2021
- Language
- EN
- Field
- Medicine (Health Sciences)